Abstract:
The present invention relates to the use of oligosaccharide mixtures for the treatment and/or prevention of infections, in particular for reducing the severity of childhood infection or the treatment and/or prevention of childhood infection.
Abstract:
The present invention relates to a nutritional product for HIV patients. More specifically the invention relates to a nutritional composition that provides carefully selected nutritional ingredients including oligosaccharides and cysteine and/or a source of cysteine specifically supporting HIV patients with nutritionally related symptoms. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.
Abstract:
A composition comprising Bifidobacterium breve, a non-digestible saccharide A and a non-digestible saccharide B, optionally combined with Lactobacillus paracasei and the use of said composition for the treatment and/or prevention of gastro-intestinal disorder, immune disorder and/or endocrine disorder.
Abstract:
The present invention relates to a method for enhancing the immune system and the treatment and/or prevention of immune system related disorders in a mammal, particularly newborns, said method comprising the administration of acid oligosaccharide and neutral oligosaccharide. Food compositions suitable for use in the above method are also provided.
Abstract:
The present invention provides novel use for live (probiotic) lactic acid producing bacteria, dead or non-viable bacteria thereof, as well as food supplements, nutritive compositions and/or pharmaceutical compositions comprising these, for the treatment or prophylaxis of lung dysfunction in a subject. A suitable lactic acid producing bacterium has a significant beneficial effect on airway narrowing determined by measuring the enhanced pause value (Penti) of a test animal.
Abstract:
The invention pertains to the use of a livestrain of the Lactobacillus casei groupfor stimulating dendritic cellsin an individual so as to increase the level of plasmacytoid dendritic cells.The plasmacytoid dendritic cells are capable of protecting the individual against herpes simplex virus type 1 infection. The live Lactobacillus caseistrain is preferably the L. casei strain with deposit number CNCM I-1518or the L. rhamnosus strain with deposit number LMG P-22799.The strain can be incorporated in a food product.
Abstract:
The present invention relates to a nutritional, preferably enteral, composition for use in the treatment of cow's milk allergy in infants allergic to cow's milk containing specific beta-lactoglobulin peptides, which are able to reduce, in particular abolish the acute symptoms of cow's milk protein allergy.
Abstract:
The present invention relates to a method for enhancing vaccination response and/or preventing infections in a human subject later in life, by- administering said human subject a nutritional composition with a specific fat composition having a defined weight ratio of linoleic acid to alpha-linolenic acid when said human subject is an infant with an age between 0 and 36 months.
Abstract:
The present invention provides infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.
Abstract:
The present invention provides infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.